HHLR Advisors’s Kura Oncology KURA Stock Holding History

HHLR Advisors’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-650,000	Closed	-$13.6M	–	98
2021 Q2	$13.6M	Hold	650,000	–	–	0.14%	62
2021 Q1	$18.4M	Hold	650,000	–	–	0.18%	51
2020 Q4	$21.2M	Buy	+650,000	New	+$22.8M	0.17%	56

Other funds holding KURA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

HHLR Advisors's KURA Position: Q3 2021 in Review

HHLR Advisors sold out of Kura Oncology (KURA) in Q3 2021, closing a stake of 650,000 shares — an estimated $13.6M sold.

HHLR Advisors first reported a position in KURA in Q4 2020 and held it in 3 quarters. The position peaked at $21.2M in Q4 2020. 152 funds tracked by Wall St. Rank hold KURA as of Q3 2021.

HHLR Advisors reported no remaining Kura Oncology position as of Q3 2021 after selling out during the quarter.
HHLR Advisors sold 650,000 Kura Oncology shares in Q3 2021, an estimated $13.6M.
HHLR Advisors first reported a position in Kura Oncology in Q4 2020 and held it in 3 quarters.
HHLR Advisors's Kura Oncology position peaked at $21.2M in Q4 2020.
152 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2021.

Based on HHLR Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.